Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant

Saved in:
Bibliographic Details
Published in:Haematologica (Roma) 2024-02, Vol.109 (2), p.689-692
Main Authors: Begna, Kebede H, Abdallah, Nadine H, Janania-Martinez, Michelle, Mangaonkar, Abhishek A, Rangan, Aruna, Herrick, Jennifer L, Gangat, Naseema
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal
Brentuximab Vedotin
Case Report
Hematopoietic Stem Cell Transplantation
Humans
Immunoconjugates - therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Stem Cell Transplantation
T-Lymphocytes
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 692
container_issue 2
container_start_page 689
container_title Haematologica (Roma)
container_volume 109
creator Begna, Kebede H
Abdallah, Nadine H
Janania-Martinez, Michelle
Mangaonkar, Abhishek A
Rangan, Aruna
Herrick, Jennifer L
Gangat, Naseema
description
doi_str_mv 10.3324/haematol.2023.283740
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a20e640326674f85b94240a95a44cf97</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a20e640326674f85b94240a95a44cf97</doaj_id><sourcerecordid>2864896846</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-c25200c2c6abfe77ce969ad48e4e97f9ba55db8ed18003d6f11df3b76aec82003</originalsourceid><addsrcrecordid>eNpVkttu1DAQhiMEokvhDRDyJTdZHNvx4QqhcqpUiZtybU2cyW6KEy-2s2JfiafE2-1W9MryzPzfHPRX1duGrjln4sMWcIIc_JpRxtdMcyXos2rVtIbVWrHmebWi3NBaUqUvqlcp3VHKqDHqZXXBlaKS83ZV_f0MEfIyLRN0BOaedBHnvPwZj_899iGPM3Fh6sYZ8hhmkrcYYXcgJXxbO_SegFsyEn-YdtvQeUh5dMTj8gunEUjEIYLLIR5IDgU07wu-cMATt8UpnHHH1uB92OCMRZ8yTuSeniPMaedhzq-rFwP4hG8e3svq59cvt1ff65sf366vPt3UTjCRa8daRqljTkI3oFIOjTTQC40CjRpMB23bdxr7RlPKezk0TT_wTklAp4uSX1bXJ24f4M7uYjlFPNgAo70PhLixEMuSHi0wilJQzqRUYtBtZ8oIFEwLQrjBqML6eGLtlm7C3pXlI_gn0KeZedzaTdjbhmqmlWSF8P6BEMPvBVO205iOl4EZw5Is01JoI7WQpVScSl0MKZXLP_ZpqD16xp49Y4-esSfPFNm7_2d8FJ1Nwv8BJ8bGFw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2864896846</pqid></control><display><type>article</type><title>Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant</title><source>PubMed Central (Open access)</source><source>Science Journals (Open access)</source><creator>Begna, Kebede H ; Abdallah, Nadine H ; Janania-Martinez, Michelle ; Mangaonkar, Abhishek A ; Rangan, Aruna ; Herrick, Jennifer L ; Gangat, Naseema</creator><creatorcontrib>Begna, Kebede H ; Abdallah, Nadine H ; Janania-Martinez, Michelle ; Mangaonkar, Abhishek A ; Rangan, Aruna ; Herrick, Jennifer L ; Gangat, Naseema</creatorcontrib><identifier>ISSN: 0390-6078</identifier><identifier>ISSN: 1592-8721</identifier><identifier>EISSN: 1592-8721</identifier><identifier>DOI: 10.3324/haematol.2023.283740</identifier><identifier>PMID: 37706335</identifier><language>eng</language><publisher>Italy: Fondazione Ferrata Storti</publisher><subject>Antibodies, Monoclonal ; Brentuximab Vedotin ; Case Report ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunoconjugates - therapeutic use ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Stem Cell Transplantation ; T-Lymphocytes</subject><ispartof>Haematologica (Roma), 2024-02, Vol.109 (2), p.689-692</ispartof><rights>Copyright© 2024 Ferrata Storti Foundation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10828762/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10828762/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37706335$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Begna, Kebede H</creatorcontrib><creatorcontrib>Abdallah, Nadine H</creatorcontrib><creatorcontrib>Janania-Martinez, Michelle</creatorcontrib><creatorcontrib>Mangaonkar, Abhishek A</creatorcontrib><creatorcontrib>Rangan, Aruna</creatorcontrib><creatorcontrib>Herrick, Jennifer L</creatorcontrib><creatorcontrib>Gangat, Naseema</creatorcontrib><title>Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant</title><title>Haematologica (Roma)</title><addtitle>Haematologica</addtitle><subject>Antibodies, Monoclonal</subject><subject>Brentuximab Vedotin</subject><subject>Case Report</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Immunoconjugates - therapeutic use</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Stem Cell Transplantation</subject><subject>T-Lymphocytes</subject><issn>0390-6078</issn><issn>1592-8721</issn><issn>1592-8721</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkttu1DAQhiMEokvhDRDyJTdZHNvx4QqhcqpUiZtybU2cyW6KEy-2s2JfiafE2-1W9MryzPzfHPRX1duGrjln4sMWcIIc_JpRxtdMcyXos2rVtIbVWrHmebWi3NBaUqUvqlcp3VHKqDHqZXXBlaKS83ZV_f0MEfIyLRN0BOaedBHnvPwZj_899iGPM3Fh6sYZ8hhmkrcYYXcgJXxbO_SegFsyEn-YdtvQeUh5dMTj8gunEUjEIYLLIR5IDgU07wu-cMATt8UpnHHH1uB92OCMRZ8yTuSeniPMaedhzq-rFwP4hG8e3svq59cvt1ff65sf366vPt3UTjCRa8daRqljTkI3oFIOjTTQC40CjRpMB23bdxr7RlPKezk0TT_wTklAp4uSX1bXJ24f4M7uYjlFPNgAo70PhLixEMuSHi0wilJQzqRUYtBtZ8oIFEwLQrjBqML6eGLtlm7C3pXlI_gn0KeZedzaTdjbhmqmlWSF8P6BEMPvBVO205iOl4EZw5Is01JoI7WQpVScSl0MKZXLP_ZpqD16xp49Y4-esSfPFNm7_2d8FJ1Nwv8BJ8bGFw</recordid><startdate>20240201</startdate><enddate>20240201</enddate><creator>Begna, Kebede H</creator><creator>Abdallah, Nadine H</creator><creator>Janania-Martinez, Michelle</creator><creator>Mangaonkar, Abhishek A</creator><creator>Rangan, Aruna</creator><creator>Herrick, Jennifer L</creator><creator>Gangat, Naseema</creator><general>Fondazione Ferrata Storti</general><general>Ferrata Storti Foundation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240201</creationdate><title>Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant</title><author>Begna, Kebede H ; Abdallah, Nadine H ; Janania-Martinez, Michelle ; Mangaonkar, Abhishek A ; Rangan, Aruna ; Herrick, Jennifer L ; Gangat, Naseema</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-c25200c2c6abfe77ce969ad48e4e97f9ba55db8ed18003d6f11df3b76aec82003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibodies, Monoclonal</topic><topic>Brentuximab Vedotin</topic><topic>Case Report</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Immunoconjugates - therapeutic use</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Stem Cell Transplantation</topic><topic>T-Lymphocytes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Begna, Kebede H</creatorcontrib><creatorcontrib>Abdallah, Nadine H</creatorcontrib><creatorcontrib>Janania-Martinez, Michelle</creatorcontrib><creatorcontrib>Mangaonkar, Abhishek A</creatorcontrib><creatorcontrib>Rangan, Aruna</creatorcontrib><creatorcontrib>Herrick, Jennifer L</creatorcontrib><creatorcontrib>Gangat, Naseema</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Haematologica (Roma)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Begna, Kebede H</au><au>Abdallah, Nadine H</au><au>Janania-Martinez, Michelle</au><au>Mangaonkar, Abhishek A</au><au>Rangan, Aruna</au><au>Herrick, Jennifer L</au><au>Gangat, Naseema</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant</atitle><jtitle>Haematologica (Roma)</jtitle><addtitle>Haematologica</addtitle><date>2024-02-01</date><risdate>2024</risdate><volume>109</volume><issue>2</issue><spage>689</spage><epage>692</epage><pages>689-692</pages><issn>0390-6078</issn><issn>1592-8721</issn><eissn>1592-8721</eissn><cop>Italy</cop><pub>Fondazione Ferrata Storti</pub><pmid>37706335</pmid><doi>10.3324/haematol.2023.283740</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0390-6078
ispartof Haematologica (Roma), 2024-02, Vol.109 (2), p.689-692
issn 0390-6078
1592-8721
1592-8721
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a20e640326674f85b94240a95a44cf97
source PubMed Central (Open access); Science Journals (Open access)
subjects Antibodies, Monoclonal
Brentuximab Vedotin
Case Report
Hematopoietic Stem Cell Transplantation
Humans
Immunoconjugates - therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Stem Cell Transplantation
T-Lymphocytes
title Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T13%3A55%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Daratumumab%20and%20brentuximab%20vedotin%20combination%20therapy%20in%20T-cell%20acute%20lymphoblastic%20leukemia%20refractory%20to%20conventional%20chemotherapy%20and%20allogeneic%20stem%20cell%20transplant&rft.jtitle=Haematologica%20(Roma)&rft.au=Begna,%20Kebede%20H&rft.date=2024-02-01&rft.volume=109&rft.issue=2&rft.spage=689&rft.epage=692&rft.pages=689-692&rft.issn=0390-6078&rft.eissn=1592-8721&rft_id=info:doi/10.3324/haematol.2023.283740&rft_dat=%3Cproquest_doaj_%3E2864896846%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c424t-c25200c2c6abfe77ce969ad48e4e97f9ba55db8ed18003d6f11df3b76aec82003%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2864896846&rft_id=info:pmid/37706335&rfr_iscdi=true